Peer-reviewed veterinary case report
Ovariohysterectomy for treating mammary growths in female cats
By de Melo, Evelynne Hm et al.·Published in Journal of feline medicine and surgery·2021·Department of Veterinary Medicine, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effectiveness of ovariohysterectomy on feline mammary fibroepithelial hyperplasia treatment.
- Species:
- cat
Plain-English summary
A group of 79 female cats diagnosed with mammary fibroepithelial hyperplasia (a condition causing abnormal growth in the mammary glands) were treated with ovariohysterectomy (spaying) to see if it would help. Most cats (about 92%) showed complete improvement after the surgery, but those who had received previous progestin injections before their diagnosis had a harder time recovering and were more likely to have ongoing growth in their mammary glands. The study suggests that spaying is an effective treatment for this condition, especially if no breeding is planned, and that additional treatment may be needed if growth persists after surgery.
People also search for: cat mammary gland growth treatment · spaying cats with fibroepithelial hyperplasia · feline mammary tumor surgery recovery
Abstract
OBJECTIVES: The aim of this study was to evaluate the effectiveness of ovariohysterectomy (OVH) on feline mammary fibroepithelial hyperplasia (FMFH) treatment, as well as the influence of previous injectable progestin on clinical signs and treatment of FMFH. METHODS: Seventy-nine female cats diagnosed with FMFH between 2014 and 2018 were included. The animals were distributed as follows: (1) treated only with OVH (TA) or OVH plus antiprogestin (TB); and (2) no administration (G1) or previous administration (G2) of injectable progestin before FMFH diagnosis. Data regarding clinical signs of FMFH, occurrence of persistent mammary growth after OVH, and time until complete remission of FMFH post-surgery were recorded and evaluated. RESULTS: Mastectomy was not performed in any cat during the study. TA was adopted in 71/79 (89.9%) cases, with 42/71 (59.2%) from G2 and 29/71 (40.8%) from G1. TB was adopted in 8/79 (10.1%) cats, all from G2. Total remission of FMFH was observed in 73/79 (92.4%) cats, with six animals from G2 having died (n = 6/79 [7.6%]). The time until complete remission of FMFH was higher (<0.0001) in cats from G2 than from G1. Moreover, animals from G2 had a higher percentage of persistent mammary growth after OVH (<0.001) and a tendency to higher mortality ( = 0.052) compared with G1. CONCLUSIONS AND RELEVANCE: Previous treatment with injectable progestin may result in a more complex clinical presentation of FMFH. Ovariohysterectomy is a good treatment option for FMFH when there is no interest in breeding the queen. Treatment with antiprogestin is recommended, especially if persistent mammary growth is detected after OVH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32812465/